+65 3158 9940
1300 798 820
+64 9801 0299
P1=Phase I; P2=Phase II; P3=Phase III; RF=Regulatory Filing & Approval
Breast: Metastatic
Breast: Metastatic (triple negative, 1st-line) + carboplatin
Breast: Metastatic (triple negative, 1st-line) + atezolizumab
Breast: Early (neoadjuvant)
Breast: Early (triple negative, 1st-line) + carboplatin + atezolizumab
Breast: Early (triple negative) + pembrolizumab
Pancreatic: Metastatic (1st-line) + gemcitabine
Pancreatic: Adjuvant + gemcitabine
Lung: Advanced NSCLC (1st-line) + carboplatin
Lung: Adv Non-squamous NSCLC (1st-line)+ carboplatin + atezolizumab
Melanoma: Metastatic
HER2+ Early Breast Cancer (extended adjuvant)
HER2+ Metastatic Breast Cancer (3rd line)
Metastatic Breast Cancer (HER2 non-amplified, HER2 mutant)
HER2+ Metastatic Breast Cancer (combination with T-DM1)
Metastatic Breast Cancer with Brain Metastases
Early Breast Cancer (neoadjuvant) I-SPY 2
Solid Tumours with EGFR mutations (basket trial)
Small Cell Lung Cancer (SCLC)
BRCA 1/2 Breast Cancer
Cancer – Basket Trial
Mesothelioma
Mesothelioma (SEALIGHT)
Relapsed SCLC (LAGOON)
Leiomyosarcoma and Liposarcoma
Refractory/Relapsed GIST (INVICTUS)
GIST (2nd Line) (INTRIGUE)
Breast Cancer Assay (Node -) (TAILORx)
Breast Cancer Assay (Node +) (RxPONDER)
DCIS Assay (DUCHESS)
Colon Cancer Assay
Cholangiocarcinoma (previously treated) FIGHT-202
Cholangiocarcinoma (previously untreated) FIGHT-302
Nasopharyngeal Carcinoma
P1=Phase I; P2=Phase II; P3=Phase III; RF=Regulatory Filling & Approval
COVID-19 Treatments
Refractory / relapsed multiple myeloma
KRAS+ Non-Small Cell Lung Cancer (NSCLC, Oral)
High-Risk Myelodysplastic Syndrome (MDS) (2nd line IV)
Relapsed/refractory diffuse large B-cell lymphoma (DLBCL)
Newly Diagnosed diffuse large B-cell lymphoma (DLBCL)
Cancer anorexia-cachexia in NSCLC patients
Diabetic macular oedema
Visualisation during surgery for malignant glioma
Amyotrophic Lateral Sclerosis (ADORE)
To learn more about the clinical trials that are underway and to find out if a study is enrolling patients in your area, please visit www.clinicaltrials.gov